April 2015

4/22/2015 — Novo Nordisk A/S  launched its obesity drug Saxenda in the U.S., at a substantial price tag of $1,068 per month, according to a report by Reuters. The drug will enter an already crowded weight loss market, face physicians as well as patients who don’t really see obesity as a disease, at a premium […]

April 20, 2015 – Marketdata Enterprises has released its new 13th edition report: “The U.S. Weight Loss & Diet Control Market”, a 435-page in-depth analysis with 35 competitor profiles and 160+ tables. The $65 bill. U.S. weight loss market is in transition and is moving to toward medical programs and non-traditional retail outlets. Obamacare is

April 6, 2015 — The company announced a massive board overhaul. CEO Michael MacDonald acknowledged that activists did play a part in shaping the changes at Medifast. Eight people will leave the company’s board as the body shrinks from 12 people to nine. Activists, including Glenn W. Welling of California-based Engaged Capital LLC, sped the